If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor ...

Dexcom (Nasdaq:DXCM) announced today that it entered into a strategic partnership with Oura, maker of leading smart ring ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

The issue was disclosed to Synology immediately after demonstration, and within 48 hours a patch was made available which resolves the vulnerability," Midnight Blue said. "However, since the ...

In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed ...

Free unofficial patches are now available for a new Windows Themes zero-day vulnerability that allows attackers to steal a target's NTLM credentials remotely. NTLM has been extensively exploited ...

The patch designed to fix a bunch of problems is proving to be problematic itself, as noted by Windows Latest. The major glitch seems to be that it won't even install for some people. Certain ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S. declined year over year despite overall sales coming in slightly ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the ...

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at $75.00. Patrick Wood has given his Hold rating due to a ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.